299 related articles for article (PubMed ID: 37031748)
21. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Nieto Y; Popat U; Anderlini P; Valdez B; Andersson B; Liu P; Hosing C; Shpall EJ; Alousi A; Kebriaei P; Qazilbash M; Parmar S; Bashir Q; Shah N; Khouri I; Rondon G; Champlin R; Jones RB
Biol Blood Marrow Transplant; 2013 Mar; 19(3):410-7. PubMed ID: 23128322
[TBL] [Abstract][Full Text] [Related]
22. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J; Hellmann A; Siritanaratkul N; Ozsan GH; Ozcan M; Chuncharunee S; Goh AS; Jurczak W; Koren J; Paszkiewicz-Kozik E; Wang B; Singh S; Huebner D; Engert A; von Tresckow B
Br J Haematol; 2018 Nov; 183(3):400-410. PubMed ID: 30168134
[TBL] [Abstract][Full Text] [Related]
23. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes.
Brammer JE; Chihara D; Poon LM; Caimi P; de Lima M; Ledesma C; Rondon G; Ciurea SO; Nieto Y; Fanale M; Dabaja B; Maziarz RT; Champlin RE; Hosing C; Oki Y
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e41-e50. PubMed ID: 29277360
[TBL] [Abstract][Full Text] [Related]
24. High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Cocorocchio E; Peccatori F; Vanazzi A; Piperno G; Calabrese L; Botteri E; Travaini L; Preda L; Martinelli G
Hematol Oncol; 2013 Mar; 31(1):34-40. PubMed ID: 22473680
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
26. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
27. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
[TBL] [Abstract][Full Text] [Related]
28. Pre-transplant (18)F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT.
Akhtar S; Al-Sugair AS; Abouzied M; Alkadhi Y; Dingle M; Abdelsalam M; Soudy H; Darwish A; Eltigani A; Elhassan TA; Nabil-Ahmed M; Maghfoor I
Bone Marrow Transplant; 2013 Apr; 48(4):551-6. PubMed ID: 22964592
[TBL] [Abstract][Full Text] [Related]
29. High-dose chemotherapy and autologous stem cell transplantation for Hodgkin's lymphoma in the kingdom of Saudi Arabia: King Faisal specialist hospital and research center experience.
Akhtar S; Abdelsalam M; El Weshi A; Al Husseini H; Janabi I; Rahal M; Maghfoor I
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S37-S40. PubMed ID: 18724297
[TBL] [Abstract][Full Text] [Related]
30. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
[TBL] [Abstract][Full Text] [Related]
31. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
[TBL] [Abstract][Full Text] [Related]
32. High-dose chemotherapy and autologous stem cell transplant in adolescent patients with relapsed or refractory Hodgkin's lymphoma.
Akhtar S; El Weshi A; Rahal M; Abdelsalam M; Al Husseini H; Maghfoor I
Bone Marrow Transplant; 2010 Mar; 45(3):476-82. PubMed ID: 19734949
[TBL] [Abstract][Full Text] [Related]
33. High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma.
Rancea M; Monsef I; von Tresckow B; Engert A; Skoetz N
Cochrane Database Syst Rev; 2013 Jun; (6):CD009411. PubMed ID: 23784872
[TBL] [Abstract][Full Text] [Related]
34. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.
Song Y; Yin Q; Wang J; Wang Z
Cell Transplant; 2021; 30():9636897211057077. PubMed ID: 34743574
[TBL] [Abstract][Full Text] [Related]
35. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H; Reinhardt A; Barnett M; Kundu S; Hosing C; Ramdial J; Saini N; Srour S; Alousi A; Kebriaei P; Popat U; Qazilbash M; Champlin R; Shpall EJ; Gulbis A; Shigle TL; Dabaja B; Pinnix C; Ahmed S; Steiner R; Andersson BS; Nieto Y
Transplant Cell Ther; 2023 Nov; 29(11):690-694. PubMed ID: 37607645
[TBL] [Abstract][Full Text] [Related]
36. Tandem high-dose chemotherapy with topotecan-thiotepa-carboplatin and melphalan-etoposide-carboplatin regimens for pediatric high-risk brain tumors.
Choi JY; Kang HJ; Hong KT; Hong CR; Lee YJ; Park JD; Phi JH; Kim SK; Wang KC; Kim IH; Park SH; Choi YH; Cheon JE; Park KD; Shin HY
Int J Clin Oncol; 2019 Dec; 24(12):1515-1525. PubMed ID: 31352632
[TBL] [Abstract][Full Text] [Related]
37. Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation.
Kim JW; Kim BS; Bang SM; Kim I; Kim DH; Kim WS; Yang DH; Lee JJ; Lee JH; Kim JS; Sohn SK; Yhim HY; Kwak JY; Yoon SS; Lee JS; Park S; Kim BK;
Ann Hematol; 2011 Dec; 90(12):1409-18. PubMed ID: 21468694
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.
Kopińska A; Koclęga A; Wieczorkiewicz-Kabut A; Woźniczka K; Kata D; Włodarczyk M; Helbig G
Pathol Oncol Res; 2021; 27():1609867. PubMed ID: 34385892
[No Abstract] [Full Text] [Related]
39. Nitrosourea, etoposide and cyclophosphamide followed by autologous stem cell transplantation for pediatric lymphoma patients.
Choi JY; Kang HJ; An HY; Hong KT; Shin HY
Int J Hematol; 2020 Jun; 111(6):877-887. PubMed ID: 32215821
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]